NasdaqCM - Nasdaq Real Time Price USD

Telomir Pharmaceuticals, Inc. (TELO)

Compare

2.4800

-0.0100

(-0.40%)

At close: April 17 at 4:00:00 PM EDT

2.6500

+0.17

+(6.85%)

After hours: April 17 at 7:27:59 PM EDT

Telomir Pharmaceuticals Announces Significant Anti-Cancer Effects in Prostate Cancer Animal Model Using Highly Aggressive Human Prostate Cancer Cells

Telomir-1 Inhibits Tumor Growth, Suppresses Cancer Progression, and Neutralizes Chemotherapy Toxicity MIAMI, FLORIDA / ACCESS Newswire / March 19, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir"), a leader in age-reversal science, today ...

ACCESS Newswire 29 days ago

TELO
-0.40%
TELO Study Shows Cancer-Related Breakthrough

By Brad Sorensen, CFA NASDAQ:TELO READ THE FULL TELO RESEARCH REPORT Telomir Pharmaceuticals (NASDAQ:TELO) is a preclinical stage biopharmaceutical company developing a product designed to lengthen the DNA’s protective telomere caps. Previously reported preclinical tests have shown evidence that Telomir-1, the company’s primary therapy, can lengthen telomeres and initial animal testing

Zacks Small Cap Research 29 days ago

TELO
-0.40%
Telomir Pharmaceuticals Announces Breakthrough: Telomir-1 Reverses Calcium Dysregulation, the Hidden Driver of Aging and Disease, in Multiple Human Cell Lines

New Study Confirms Telomir-1 Also Reverses Oxidative Stress, Preserves Cellular Integrity, and Prevents Cell Death by Protecting Mitochondria-The Cell's Power Source and Gatekeeper of Life and Death MIAMI, FLORIDA / ACCESS Newswire / February 26, ...

ACCESS Newswire last month

TELO
-0.40%
3 US Penny Stocks To Consider In February 2025

As of February 2025, U.S. markets have been experiencing a mixed performance, with the S&P 500 and Nasdaq falling for the fourth consecutive day amid concerns about economic outlook and policy impacts. Despite these challenges, investors often look to penny stocks as a potential area for growth due to their affordability and the unique opportunities they present. While once considered speculative, penny stocks can still offer compelling prospects when backed by strong financials, making them...

Simply Wall St. last month

CCG

CCGWW

PMVP
Telomir Pharmaceuticals Says Telomir-1 Compound Stabilizes Silver for Advanced Medical Applications

Telomir Pharmaceuticals (TELO) said Friday it was able to stabilize both Silver(I) and the highly re

PREMIUM
MT Newswires last month

TELO
-0.40%
Telomir Pharmaceuticals Achieves Breakthrough in Silver Ion Stabilization, Unlocking a Multi-Billion-Dollar Medical Market

MIAMI, FLORIDA / ACCESS Newswire / February 21, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or Telomir, a leader in age-reversal science, today announced a breakthrough achievement-Telomir-1 has successfully captured and stabilized both Silver(I) ...

ACCESS Newswire last month

TELO
-0.40%
TELO Announces Breakthrough

By Brad Sorensen, CFA NASDAQ:TELO READ THE FULL TELO RESEARCH REPORT Telomir Pharmaceuticals (NASDAQ:TELO) is a preclinical stage biopharmaceutical company developing a product designed to lengthen the DNA’s protective telomere caps. Previously reported preclinical tests have shown evidence that Telomir-1, the company’s primary therapy, can lengthen telomeres and initial animal testing

Zacks Small Cap Research last month

TELO
-0.40%
Telomir Pharmaceuticals Seeks To Tap Multi-Billion-Dollar Market With Breakthrough In Silver Ion Stabilization For Antibacterial Treatment, Tissue Regeneration

On Thursday, Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) announced the company’s Telomir-1 captured and stabilized Silver(I) (Ag⁺) and the highly reactive Silver (II) (Ag²⁺) in a biologically compatible form. Telomir-1 is a small-molecule metal ion chelator and regulator designed to lengthen the DNA’s protective telomere caps, which are crucial in the aging process. It is in preclinical development. What Happened: While Silver(I) compounds have demonstrated antibacterial activity, Silver(II) off

Benzinga last month

TELO
-0.40%
Telomir Pharmaceuticals Announces Significant Reduction of Oxidative Stress in Human Retinal Cell Lines, Advancing Potential Treatment for Age-Related Macular Degeneration (AMD)

MIAMI, FLORIDA / ACCESS Newswire / February 18, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or Telomir, a leader in age-reversal science, today announced groundbreaking results from its recent preclinical studies conducted in human retinal ...

ACCESS Newswire last month

TELO
-0.40%
TELO Again Announces Breakthrough Results

By Brad Sorensen, CFA NASDAQ:TELO READ THE FULL TELO RESEARCH REPORT Telomir Pharmaceuticals (NASDAQ:TELO) is a preclinical stage biopharmaceutical company developing a product designed to lengthen the DNA’s protective telomere caps. Previously reported preclinical tests have shown evidence that Telomir-1, the company’s primary therapy, can lengthen telomeres and initial animal testing

Zacks Small Cap Research last month

TELO
-0.40%
TELO Improves Balance Sheet

By Brad Sorensen, CFA NASDAQ:TELO READ THE FULL TELO RESEARCH REPORT Telomir Pharmaceuticals (NASDAQ:TELO) is a preclinical stage biopharmaceutical company developing a product designed to lengthen the DNA’s protective telomere caps. Previously reported preclinical tests have shown evidence that Telomir-1, the company’s primary therapy, can lengthen telomeres and initial animal testing

Zacks Small Cap Research 2 months ago

TELO
-0.40%
Telomir Pharmaceuticals Announces Breakthrough Results With Telomir-1 Fully Reversing Oxidative Stress in Human Cell Lines and Exploring Potential as a Treatment for Avian Influenza (Bird Flu) and Other Viruses

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or Telomir, a leader in age-reversal science, today announced groundbreaking results from its recent preclinical studies conducted in human cell lines. These studies demonstrated the ability of Telomir-1 ...

ACCESS Newswire 2 months ago

TELO
-0.40%
TELO Treatment Amazes in Preclinical Trial

By Brad Sorensen, CFA NASDAQ:TELO READ THE FULL TELO RESEARCH REPORT Telomir Pharmaceuticals (NASDAQ:TELO) is a preclinical stage biopharmaceutical company developing a product designed to lengthen the DNA’s protective telomere caps. Previously reported preclinical tests have shown evidence that Telomir-1, the company’s primary therapy, can lengthen telomeres and initial animal testing

Zacks Small Cap Research 2 months ago

TELO
-0.40%
Telomir Pharmaceuticals, Inc.'s (NASDAQ:TELO) biggest owners are retail investors who got richer after stock soared 13% last week

Key Insights Significant control over Telomir Pharmaceuticals by retail investors implies that the general public has...

Simply Wall St. 2 months ago

TELO
-0.40%
Zacks Small Cap Research 2024 Initiations and Best Ideas for 2025

Zacks Small Cap Research was hard at work in 2024 initiating analyst coverage on 40 companies. Each of our initiation reports provides a valuation, investment thesis and financial forecast model that comes from our 11 experienced analysts’ expertise and due diligence. Our work has generated investment ideas in health care, consumer electronics, finance technologies, transportation, AI-based

Zacks Small Cap Research 3 months ago

MTVA

LGNZZ

TELO
-0.40%
Telomir Pharmaceuticals Confirms Lifespan Restoration and Normalization of Accelerated Aging in Preclinical Model of Progeria (A Rare Genetic Disorder Causing Rapid Aging)

MIAMI, FL / ACCESSWIRE / January 7, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir"), an emerging leader in age-reversal science focused on treating the root causes of diseases rather than just their symptoms, announced today potentially ...

ACCESS Newswire 3 months ago

TELO
-0.40%
TELO Continues to Impress

By Brad Sorensen, CFA NASDAQ:TELO READ THE FULL TELO RESEARCH REPORT Telomir Pharmaceuticals (NASDAQ:TELO) is a preclinical stage biopharmaceutical company developing a product designed to lengthen the DNA’s protective telomere caps. Previously reported preclinical tests have shown evidence that Telomir-1, the company’s primary therapy, can lengthen telomeres and initial animal testing

Zacks Small Cap Research 3 months ago

TELO
-0.40%
Telomir Pharmaceuticals Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline Into Wilson's Disease

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or the "Company", an emerging leader in age-reversal science, today announced significant findings from its copper binding studies with Telomir-1. This is a promising development as the company explores ...

ACCESS Newswire 3 months ago

TELO
-0.40%
EXCLUSIVE: Telomir Pharmaceuticals Reports Potential Of Telomir-1 For Wilson's Disease

On Monday, Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) announced preclinical findings highlighting the copper-binding potential of its lead compound, Telomir-1, as a promising treatment for Wilson's disease and related disorders. The compound exhibits a binding affinity for copper ions, enabling precise regulation of copper metabolism and interacting with essential ions such as copper, iron, and zinc, the company said. Recent preclinical studies by Recipharm and Smart Assays reveal Telomir-1's s

Benzinga 3 months ago

TELO
-0.40%
Telomir Pharmaceuticals Raises $1 Million at $7 per Share in a No-Warrant, Restricted Common Stock Deal, Representing a 20% Premium to Closing Price

MIAMI, FL / ACCESSWIRE / December 12, 2024 / Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) ("Telomir" or the "Company"), an emerging leader in age-reversal science, today announced it has raised $1 million in equity funding through The Starwood Trust. ...

ACCESS Newswire 4 months ago

TELO
-0.40%

Performance Overview

Return	TELO	S&P 500 (^GSPC)
YTD	-39.81%	-10.18%
1-Year	-70.75%	+5.19%
3-Year	-64.57%	+20.26%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Telomir Pharmaceuticals, Inc. (TELO)

Telomir Pharmaceuticals Announces Significant Anti-Cancer Effects in Prostate Cancer Animal Model Using Highly Aggressive Human Prostate Cancer Cells

TELO Study Shows Cancer-Related Breakthrough

Telomir Pharmaceuticals Announces Breakthrough: Telomir-1 Reverses Calcium Dysregulation, the Hidden Driver of Aging and Disease, in Multiple Human Cell Lines

3 US Penny Stocks To Consider In February 2025

Telomir Pharmaceuticals Says Telomir-1 Compound Stabilizes Silver for Advanced Medical Applications

Telomir Pharmaceuticals Achieves Breakthrough in Silver Ion Stabilization, Unlocking a Multi-Billion-Dollar Medical Market

TELO Announces Breakthrough

Telomir Pharmaceuticals Seeks To Tap Multi-Billion-Dollar Market With Breakthrough In Silver Ion Stabilization For Antibacterial Treatment, Tissue Regeneration

Telomir Pharmaceuticals Announces Significant Reduction of Oxidative Stress in Human Retinal Cell Lines, Advancing Potential Treatment for Age-Related Macular Degeneration (AMD)

TELO Again Announces Breakthrough Results

TELO Improves Balance Sheet

Telomir Pharmaceuticals Announces Breakthrough Results With Telomir-1 Fully Reversing Oxidative Stress in Human Cell Lines and Exploring Potential as a Treatment for Avian Influenza (Bird Flu) and Other Viruses

TELO Treatment Amazes in Preclinical Trial

Telomir Pharmaceuticals, Inc.'s (NASDAQ:TELO) biggest owners are retail investors who got richer after stock soared 13% last week

Zacks Small Cap Research 2024 Initiations and Best Ideas for 2025

Telomir Pharmaceuticals Confirms Lifespan Restoration and Normalization of Accelerated Aging in Preclinical Model of Progeria (A Rare Genetic Disorder Causing Rapid Aging)

TELO Continues to Impress

Telomir Pharmaceuticals Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline Into Wilson's Disease

EXCLUSIVE: Telomir Pharmaceuticals Reports Potential Of Telomir-1 For Wilson's Disease

Telomir Pharmaceuticals Raises $1 Million at $7 per Share in a No-Warrant, Restricted Common Stock Deal, Representing a 20% Premium to Closing Price

Performance Overview